2007 Diabetes IT Provider 
The Health Policy Exchange
MAY 20, 2013
Unfortunately, recent case studies have illustrated that FDA approval does not necessarily provide assurances of effectiveness and safety. Although a 2007 meta-analysis first sounded the alarm about rosiglitazone's cardiovascular risks, the manufacturer successfully stalled regulatory action in the U.S.
GeriPal
FEBRUARY 17, 2022
This tool provides a clinical recommendation for starting/stopping medications and cancer screening based on the prognosis of the patient in front of you. Think of the 10 years it takes to benefit from colon or breast cancer screening, which is designed to detect slow growing cancers. See screenshot below. James: Thanks for having me.
Expert insights. Personalized for you.
130 
Let's personalize your content